Rolvedon
Payments companies reported to CMS as associated with Rolvedon. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rolvedon, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rolvedon
These are the largest totals companies reported as associated with Rolvedon. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Shanta Chawla | Irvine, CA | Internal Medicine | $17,409.52 |
| Matthew Carlson | Mckinney, TX | Gynecologic Oncology | $9,591.88 |
| Michael Mcallister | Dothan, AL | Hematology & Oncology | $2,733.53 |
| Arun Jesudian | New York, NY | Hepatology | $2,620.00 |
| Ashwani Singal | Louisville, KY | Transplant Hepatology | $1,310.00 |
| Paul Gaglio | Newark, NJ | Transplant Hepatology | $1,310.00 |
| Jasmohan Bajaj | Richmond, VA | Gastroenterology (Internal Medicine) | $1,310.00 |
| Juan Arab Verdugo | Rochester, MN | Gastroenterology (Internal Medicine) | $1,310.00 |
| Winston Dunn | Kansas City, KS | Gastroenterology (Internal Medicine) | $1,310.00 |
| Pei Lim Lee | Los Angeles, CA | Transplant Hepatology | $1,310.00 |
Prescribed Rolvedon?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.